Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors

Edward J. Wu, Dennis J. Goussetis, Elspeth Beauchamp, Ewa M. Kosciuczuk, Jessica K. Altman, Elizabeth A. Eklund, Leonidas C. Platanias*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Efforts to enhance the antileukemic properties of arsenic trioxide are clinically relevant and may lead to the development of new therapeutic approaches for the management of certain hematological malignancies. We provide evidence that concomitant treatment of acute myeloid leukemia (AML) cells or chronic myeloid leukemia (CML) cells with resveratrol potentiates arsenic trioxide-dependent induction of apoptosis. Importantly, clonogenic assays in methylcellulose demonstrate potent suppressive effects of the combination of these agents on primitive leukemic progenitors derived from patients with AML or CML. Taken together, these findings suggest that combinations of arsenic trioxide with resveratrol may provide an approach for targeting of early leukemic precursors and, possibly, leukemia initiating stem cells.

Original languageEnglish (US)
Pages (from-to)473-478
Number of pages6
JournalCancer Biology and Therapy
Issue number4
StatePublished - Apr 2014


  • Apoptosis
  • Arsenic trioxide
  • Autophagy
  • Myeloid leukemia

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors'. Together they form a unique fingerprint.

Cite this